Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.

Our approach uses a new class of compounds called imipridones that selectively target G protein-coupled receptors (GPCRs) and ClpP to control critical signaling pathways in cancer.

MD Anderson Cancer Center and Massachusetts General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.